Once again, Ginemed is in the news for being at the forefront of innovation.
During the first week of July we attended the European Society of Human Reproduction and Embryology’s (ESHRE) annual meeting. A meeting that gathers together, once a year, the best that European reproductive medicine has to offer and, which, in 2016, held its 32nd event in Helsinki.
This year, the R&D team from Ginemed and SafePreservation, a spin-off from the University of Seville, presented a scientific paper based on the clinical results from their work on synthetic vitrification mediums.
Traditional embryo vitrification mediums, incorporate a macromolecular protein supplement of human origin as a surfactant. Typically, a combination of albumin and globulin are used, which give the medium the viscosity required so that the gametes and embryos can be manipulated.
Nonetheless, these proteins of human origin – which have been vital until now – increase the risk of contamination and have a reduced lifespan, as well as increasing the cost.
In the presentation, its principal author: Miguel Gallardo, biologist-embryologist, from the Ginemed laboratory in Lisbon, described the clinical results that demonstrate its efficiency: the survival rates of eggs vitrified using these synthetic vitrification methods being 97% and the pregnancy rate per transfer: 60%, the same as the results obtained with fresh egg donation.
This represents a substantial improvement in the safety of the gamete and human embryos cryopreservation process, which is now being used worldwide.